DURHAM, N.C., April 13, 2016 — Premier Research will have a large presence at this year’s World Orphan Drug Congress, April 21-22 in Washington, D.C. The company is a platinum sponsor of the 2016 conference, and its top medical expert will moderate a panel discussion on drug development.
At WODC, more than ever a top meeting destination for specialty pharma, biotechs, government, and patient groups, Premier Research will highlight rare disease expertise that spans 90+ studies across more than 30 indications over just the past five years. From ensuring statistically relevant endpoints in small rare disease trials to pursuing orphan drug status, the company has the experience to help customers negotiate this complex and fast-evolving field.
At 11:40 a.m. Thursday, April 21, Chief Medical Officer Colin Hayward will moderate Navigating Drug Development: Identifying Biomarkers and Surrogate Endpoints When There is No Known Natural History. Panelists will include Premier Research’s Juliet Moritz, Executive Director for Clinical Development specializing in rare diseases. Premier Research is also a sponsor in WODC’s Pitch & Partner sessions.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, CNS, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.